Senti Bio
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2 Corporate Dr Fl 1, South San Francisco...Phone Number
(650) 239-2030Website
www.sentibio.comRevenue
<$5 MillionStock Symbol
SNTIIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
2
1
1
About Senti Bio
Founded in 2016 and headquartered in South San Francisco, California, Senti Bio has built a synthetic biology platform that enables it to program next-generation cell and gene therapies with gene circuits. These gene circuits, which are created from novel and proprietary combinations of DNA sequences, reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments.Explore more
Senti Bio Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Senti Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Senti Bio has recently received funding, and reach out quickly before it becomes old news!
Check out if Senti Bio is spiking on competitors!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Senti Bio has new funding data
Congratulate Masked Content for being promoted to Masked Content at Senti Bio
Earning: See what the market has to say on Senti Bio recently announced quarterly report
Click to see if Senti Bio had a recent Job posting/layoffs
Senti Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Senti Bio launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Senti Bio
Compare insights from companies similar to Senti Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Senti Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Senti Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Senti Bio.
Senti Bio financials insights
Gather financial insights about Senti Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$53M
2021
Series B
$105M
2022
Debt
$5.2M
2025
Other Financing Round
$10M
Senti Bio Tech Stack
A closer look at the technologies used by Senti Bio
Most Recent Scoops
Person-Based
Medical Research
Person-Based
Person-Based
Earnings, Pharmaceuticals, Finance
Person-Based
Product Development, Pharmaceuticals
Project
Medical Research
Senti Bio News & Media
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program
Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center registrational trial for SENTI-202, building off the strong Phase 1 clinical results demonstrating deep and durable MRD-negative complete remissionsSenti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026
SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, Co-Founder and Chief Executive Officer of Senti, will present at the AACR Annual Meeting 2026, taking place April 17–22, 2026, in San Diego, CA.Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies
SOUTH SAN FRANCISCO, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the publication of new peer-reviewed research in Cell Systems demonstrating its systematic framework for engineering NOT-gated chimeric antigen receptor (CAR) circuits in both T cells and natural killer (NK) cells. The study demonsSenti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
SOUTH SAN FRANCISCO, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the fourth quarter of 2025 and full year 2025 and provided a summary of recent pipeline and corporate highlights.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Senti Bio
Sign Up For FreeTo access detailed company insights
Founded in 2016 and headquartered in South San Francisco, California, Senti Bio has built a synthetic biology platform that enables it to program next-generation cell and gene therapies with gene circuits. These gene circuits, which are created from novel and proprietary combinations of DNA sequences, reprogram cells with biological logic to sense... Read More
